Production (Stage)
COSCIENS Biopharma Inc.
CSCI
$3.68
$0.113.08%
NASDAQ
| 03/31/2025 | 06/30/2024 | 06/30/2024 | 03/31/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 45.70% | -1.50% | -1.50% | -118.85% | 75.14% |
| Total Depreciation and Amortization | -17.09% | 5.01% | 5.01% | -72.74% | 734.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -95.24% | -473.47% | -443.22% | 65.91% | -92.27% |
| Change in Net Operating Assets | 75.99% | 289.18% | 289.18% | -163.52% | -329.36% |
| Cash from Operations | 37.31% | 41.64% | 42.15% | -125.99% | 55.37% |
| Capital Expenditure | -99.03% | 72.16% | 72.16% | 20.34% | -11,180.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 42.86% | -- | -- | -- | -- |
| Cash from Investing | -94.62% | 4,688.65% | 4,688.65% | 21.12% | -203.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -83.49% | -34.04% | -75.00% | 63.42% | -89.47% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.99% | -34.04% | -75.00% | 61.48% | -89.47% |
| Foreign Exchange rate Adjustments | 168.18% | 50.00% | 50.37% | -191.78% | -200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 26.91% | 866.02% | 866.02% | -138.02% | 33.08% |